Point72 Asia (Singapore) Pte. Ltd. Pyxis Oncology, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 29,835 shares of PYXS stock, worth $86,521. This represents 0.03% of its overall portfolio holdings.
Number of Shares
29,835Holding current value
$86,521% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding PYXS
# of Institutions
76Shares Held
23.5MCall Options Held
88.6KPut Options Held
47K-
Deep Track Capital, LP Greenwich, CT4.18MShares$12.1 Million0.59% of portfolio
-
Laurion Capital Management LP New York, NY3.86MShares$11.2 Million0.14% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.59MShares$7.52 Million0.02% of portfolio
-
Stem Point Capital LP New York, NY1.79MShares$5.2 Million2.02% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.66MShares$4.82 Million0.94% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $102M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...